Wednesday, November 25,  4:59 pm

Forward-looking intelligence allows you time to act. View this video on our restructuring content to see how you can benefit from our expertise.

With public markets sluggish and not enough M&A to go around, what's a biotech banker to do? Drug industry dealmakers report that bankers are dipping their toes into unfamiliar waters, the bread-and-butter licensing and partnering deals that don't get the splashy headlines of M&A but provide a crucial source of cash for small companies that sell rights to promising drugs to larger firms with aging product lines.

"We're seeing a lot more activity from bankers," said Chen Schor, who runs business development for the branded-product group at Israeli generics giant Teva Pharmaceutical Industries Ltd. "They bring some order to the process," he said at an industry conference in San Francisco dedicated to licensing strategy.



Dig deeper, with Pipeline.

• 813 in-depth reports of M&A deals in the Healthcare sector
• 116 company pages related to Biotech
• 24 in-depth transaction records for Teva Pharmaceutical Industries Ltd.
• 14 in-depth transaction records for Wyeth
• 10 years of news and analysis archives from the voice of The Deal Economy
  

Most searched keywords

• Skadden Arps
• Amusement parks
• Deb Shops
• Windstream Corp.
• Diedrich Coffee
• Hanna Andersson
• Tween Brands
• Entertainment
  
• Lazard
• Lyondell Chemical